San Diego, California-based Prometheus Biosciences has entered into a global, multi-target strategic collaboration with Japan’s Takeda Pharmaceutical (TYO: 4502) to discover, develop, and commercialize novel therapies for inflammatory bowel disease (IBD).
The collaboration combines the proprietary bioinformatics discovery platform and companion diagnostic tools developed by Prometheus, which was created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD, with Takeda's expertise in gastroenterology and drug development, in order to discover and advance up to three targeted IBD therapeutics and companion diagnostics.
Financial terms
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze